
Cybin (CYBN) Stock Forecast & Price Target
Cybin (CYBN) Analyst Ratings
Bulls say
Cybin Inc. is advancing its clinical-stage pipeline with a focus on innovative therapies for neuropsychiatric conditions, notably through its Phase 3 programs CYB003 and CYB004, which are progressing towards significant data readouts in 2026. The company has demonstrated strong clinical execution and operational stability, alongside strategic partnerships, such as with ThermoFisher, that enhance its commercial readiness across its therapeutic candidates. Despite recent adjustments in launch timelines and share count due to financing, Cybin maintains a substantial potential upside, reflecting confidence in its development trajectory and financial positioning.
Bears say
The outlook for Cybin Inc. is predominantly negative due to several critical factors impacting its financial stability and growth potential. The company has recently adjusted its discounted cash flow (DCF) valuation period, leading to a decrease in the DCF-based price target from $70 to $45, primarily attributed to dilution from recent capital raises. Additionally, the inherent risks associated with developing neuropsychiatric products—such as the uncertainty of clinical trial outcomes, regulatory approval challenges, and difficulties in protecting intellectual property—further exacerbate the company's precarious position in achieving successful commercialization of its therapeutics.
This aggregate rating is based on analysts' research of Cybin and is not a guaranteed prediction by Public.com or investment advice.
Cybin (CYBN) Analyst Forecast & Price Prediction
Start investing in Cybin (CYBN)
Order type
Buy in
Order amount
Est. shares
0 shares